The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including ...

Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market GrowthRockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- ...

New York, New York-- (Newsfile Corp. - January 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

“The point is that, according to the researchers’ argument, deprivation lies on a path of cause and effect going from having ADHD to having a lower life expectancy, and adjusting for deprivation could ...

New York, New York-- (Newsfile Corp. - January 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

This allowed Regeneron and Teva to continue with trials on fasinumab, and Pfizer and Eli Lilly to resume trials into tanezumab. The latest results from Regeneron and Teva are from a sub-study in a ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of ...

CGRP Inhibitors Market. The global CGRP inhibitors market is poised for robust growth, with its valuation expected to rise ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.